110884-69-0

Upstream product

• 1517-69-7 (R)-1-phenylethanol 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 1160243-09-3 ((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid (R)-1-phenyl-ethyl ester 
• 1160243-16-2 ((2R,3R)-7-Carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid (R)-1-phenyl-ethyl ester 
• 1160243-12-8 ((2S,3S)-1,1-Diethyl-7-hydroxy-3-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid (R)-1-phenyl-ethyl ester 
• 1160243-11-7 ((2R,3R)-1,1-diethyl-7-hydroxy-3-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid (R)-1-phenyl-ethyl ester 
• 161365-75-9 1,3-Dihydro-1-methyl-5-phenyl-3(S)-<<(R)-α-methylbenzyloxycarbonyl>amino>-2H-1,4-benzodiazepin-2-one 
• 161443-31-8 1,3-Dihydro-5-phenyl-3(S)-<<(R)-α-methylbenzyloxycarbonyl>amino>-2H-1,4-benzodiazepin-2-one 

Relevant academic research and scientific papers

Condensed Azepine Derivatives As Bromodomain Inhibitors

Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

CONDENSED AZEPINE DERIVATIVES AS BROMODOMAIN INHIBITORS

Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND

The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline

AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS

The invention provides aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS

The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS

The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt the

Enantioselectivity Effects in Hydrolytic Cleavage of Activated Substrates with α- and β-Cyclodextrins

The kinetics of hydrolytic cleavage of the enantiomers of p- and m-nitrophenyl (Np) phenylacatate esters of general structure PhCR1R2-CO2-Np where R1,R2=H, Me , H, OMe , or CF3, OMe , and of the carbonates PhCHMe-OCO2-p-Np (7) and n-C6H13-CHMe-OCO2-p-Np (8), have been measured in the presence of α- and β-cyclodextrins.The rates of intracomplex cleavage were found to be larger for the R- than for the S-enantiomers in almost all cases; the enantioselectivity factors range from unity to ca. 19 depending on the relative size of the pairs of substituents R1 and R2.The effects have been interpreted with the help of molecular models.